1 ACE-INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS DO NOT IMPACT ON OUTCOME NOR IN LONG TERM CONSEQUENCES OF COVID-19. (15th December 2022)

• Record Type: Journal Article
• Authors: Salvotti, Francesca; Boari, Gianluca; Fusco, Maria Elena; Borghi, Erika; Volpe, Pietro; Tosoni, Federico; Turini, Daniele; Malerba, Paolo; Pasini, Giancarlo; Guarinoni, Vittoria; Ferrari-toninelli, Giulia; Leidi, Francesca; Bressa, Stefano; Santagiuliana, Marzia; Napoli, Federico; Geroldi, Veronica; Rosei, Claudia Agabiti; De Ciuceis, Carolina; Rizzoni, Damiano
• Is Part Of: European heart journal supplements. Volume 24(2022)Supplement K
• Publication Date: 2022-12-15
• Subjects: Cardiology -- Periodicals; Cardiology -- Europe -- Periodicals; 616.12005
• DOI: 10.1093/eurheartjsupp/suac121.383
• Languages: English
• ISSNs: 1520-765X

Abstract

Abstract: Introduction: COVID-19 pandemic still represents a major clinical problem worldwide. Many studies are actively being carried out to better understand prognostic factors of outcome as well as optimal treatment. Aim: ACE-2 receptor is highly expressed on the surface of cardiac and pulmonary cells, and it is used by coronaviruses to enter host cells; this makes the role of ACE-inhibitors and Angiotensin Receptor Blockers (ARBs) drugs controversial. Moreover, it is still unclear whether these drugs may have any impact on sequelae. Methods: In this retrospective study, we analysed a group of 244 hypertensive unvaccinated patients (134 on ACE-inhibitors, 110 on ARBs) admitted for moderate to severe COVID-19 pneumonia. As shown in the table, the two groups where homogeneous. Of these patients, 46 (20 treated with ACE-I and 26 treated with ARBs) came to a follow-up visit after a mean of 260 days; they underwent a quality-of-life assessment, laboratory and radiologic tests and spirometry (with DLCO). Results: A total of 20 of 110 (18%) patients under treatment with ARBs and 23 of 134 (17%) died during hospitalization (p=0.8, NS). At discharge, biochemical, radiological and respiratory data were not significantly different. We did not find any significant difference in terms of radiologic alterations, lung fibrosis, spirometry data, DLCO, persisting effort dyspnea. Biochemical data were substantially super-imposable in the two groups. Conclusions: we could not detect any difference in outcome nor in complications type or number in the two groups undergoing treatment with ACE-inhibitor or ARBs. This result seems to support and to strengthen the idea that ACE-inhibitors and ARBs do not play a significant role in onset, evolution and outcome of moderate to severe COVID-19 pneumoniae. Although the number of follow-up patients is small, we did not find any difference in follow-up sequelae in both groups.